Ligand Pharmaceuticals Incorporated
$ 231.82
3.84%
17 Apr - close price
- Market Cap 4,622,755,000 USD
- Current Price $ 231.82
- High / Low $ 234.31 / 225.09
- Stock P/E 37.82
- Book Value 51.44
- EPS 6.13
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.02 %
- ROE 0.14 %
- 52 Week High 234.76
- 52 Week Low 98.89
About
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover and develop drugs globally. The company is headquartered in San Diego, California.
Analyst Target Price
$246.70
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-04 | 2025-11-06 | 2025-08-08 | 2025-05-05 | 2025-02-25 | 2024-11-07 | 2024-08-06 | 2024-05-07 | 2024-02-27 | 2023-11-08 | 2023-08-08 | 2023-05-04 |
| Reported EPS | 2.02 | 3.09 | 0.24 | 1.33 | 1.27 | 1.84 | 1.4 | 1.2 | 1.38 | 1.02 | 1.42 | 2.28 |
| Estimated EPS | 1.49 | 1.93 | 1.43 | 0.78 | 1.1901 | 1.35 | 1.06 | 0.78 | 0.66 | 0.61 | 0.64 | 0.89 |
| Surprise | 0.53 | 1.16 | -1.19 | 0.55 | 0.0799 | 0.49 | 0.34 | 0.42 | 0.72 | 0.41 | 0.78 | 1.39 |
| Surprise Percentage | 35.5705% | 60.1036% | -83.2168% | 70.5128% | 6.7137% | 36.2963% | 32.0755% | 53.8462% | 109.0909% | 67.2131% | 121.875% | 156.1798% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 1.01 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | Jan 1970 | |
|---|---|---|
| Payment Date | None | None |
| Amount | $0.08 | $2.5 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LGND
2026-04-09 03:02:07
The article analyzes Ligand Pharmaceuticals Inc (LGND) financials, highlighting its revenue breakdown, profitability margins, and competitive position. Kyprolis is LGND's largest revenue contributor, accounting for 18.5% of total sales. The company demonstrates strong profitability with an 81.42% gross margin and a 75.06% net margin, outperforming competitors like AMRX in efficiency.
2026-04-04 07:09:12
John L. LaMattina, a director at Ligand Pharmaceuticals (NASDAQ: LGND), exercised non-qualified stock options for 2,161 shares at $114.15 per share and subsequently sold all those shares for $200.76 per share in an open-market transaction. Following these transactions on March 6, 2026, LaMattina directly holds 30,724 shares of Ligand common stock, with the option position now fully exercised. The net sale amounted to 2,161 shares, valued at $433,842.
2026-04-03 01:39:36
This article provides a technical analysis of Ligand Pharmaceuticals Inc (LGND), indicating a "Sell" consensus based on various indicators. It details the stock's performance relative to moving averages, its RSI, MACD readings, and key support and resistance levels. The analysis aggregates 10 technical signals, showing more sell indicators than buy indicators as of April 2, 2026.
2026-04-01 14:39:53
Ligand Pharmaceuticals Inc.'s Chief Legal Officer, Andrew Reardon, sold approximately $1.03 million in company stock after exercising options for 5,000 shares. This transaction reduced his direct holdings by nearly 12%, though he still retains substantial unexercised employee stock options. The sale occurred at a weighted average price of $206.35 per share, following Ligand's strong one-year stock performance exceeding 80%.
2026-03-27 14:39:35
The Vanguard Group filed an amended Schedule 13G/A report for Ligand Pharmaceuticals Inc. (LGND), stating it now beneficially owns 0 shares and 0% of the common stock. This change is due to an internal realignment within Vanguard, where certain subsidiaries will now report their holdings separately, as per SEC Release No. 34-39538. This filing reflects an administrative change rather than a sale or purchase of stock.
2026-03-26 04:39:02
Ligand Pharmaceuticals has appointed Peter Renehan, MD, and Lee Brown as new Vice Presidents of Investments and Business Development, both reporting to SVP Paul Hadden. Their role will focus on sourcing and executing royalty financing opportunities. Additionally, Lauren Hay has been promoted to Vice President of Portfolio Strategy and Investments, overseeing the optimization and management of Ligand's existing portfolio assets.
